Warning letter
Cohance Lifesciences Limited: warning letter of Jan 30, 2026
FDA warning letter 718812 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 718812 |
|---|---|
| Company | Cohance Lifesciences Limited |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jan 30, 2026 |
| Posted date | Feb 3, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.67(b), 211.67(a), 211.192 |
| Inspection city | Medchal-Malkajgiri |
| Inspection start date | Aug 4, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: